Annual EBITDA
-$192.16 M
-$452.32 M-173.86%
31 December 2023
Summary:
AbCellera Biologics annual earnings before interest, taxes, depreciation & amortization is currently -$192.16 million, with the most recent change of -$452.32 million (-173.86%) on 31 December 2023. During the last 3 years, it has fallen by -$361.77 million (-213.29%). ABCL annual EBITDA is now -173.86% below its all-time high of $260.17 million, reached on 31 December 2022.ABCL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$51.88 M
+$230.00 K+0.44%
30 September 2024
Summary:
AbCellera Biologics quarterly earnings before interest, taxes, depreciation & amortization is currently -$51.88 million, with the most recent change of +$230.00 thousand (+0.44%) on 30 September 2024. Over the past year, it has dropped by -$7.22 million (-16.18%). ABCL quarterly EBITDA is now -122.06% below its all-time high of $235.12 million, reached on 31 March 2022.ABCL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$202.41 M
-$7.22 M-3.70%
30 September 2024
Summary:
AbCellera Biologics TTM earnings before interest, taxes, depreciation & amortization is currently -$202.41 million, with the most recent change of -$7.22 million (-3.70%) on 30 September 2024. Over the past year, it has dropped by -$43.07 million (-27.03%). ABCL TTM EBITDA is now -154.32% below its all-time high of $372.64 million, reached on 30 September 2022.ABCL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABCL EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -173.9% | -16.2% | -27.0% |
| 3 y3 years | -213.3% | -165.9% | -165.3% |
| 5 y5 years | -10000.0% | - | - |
ABCL EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -173.9% | at low | -122.1% | +4.6% | -154.3% | at low |
| 5 y | 5 years | -173.9% | at low | -122.1% | +4.6% | -154.3% | at low |
| alltime | all time | -173.9% | at low | -122.1% | +4.6% | -154.3% | at low |
AbCellera Biologics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$51.88 M(-0.4%) | -$202.41 M(+3.7%) |
| June 2024 | - | -$52.11 M(+16.2%) | -$195.18 M(+6.9%) |
| Mar 2024 | - | -$44.85 M(-16.3%) | -$182.63 M(-5.0%) |
| Dec 2023 | -$192.16 M(-173.9%) | -$53.57 M(+20.0%) | -$192.16 M(+20.6%) |
| Sept 2023 | - | -$44.65 M(+12.9%) | -$159.33 M(+134.1%) |
| June 2023 | - | -$39.56 M(-27.3%) | -$68.07 M(+132.1%) |
| Mar 2023 | - | -$54.38 M(+162.2%) | -$29.33 M(-111.3%) |
| Dec 2022 | $260.17 M | -$20.74 M(-144.5%) | $260.17 M(-30.2%) |
| Sept 2022 | - | $46.61 M(-5784.5%) | $372.64 M(+21.6%) |
| June 2022 | - | -$820.00 K(-100.3%) | $306.51 M(-0.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $235.12 M(+156.3%) | $309.16 M(+29.2%) |
| Dec 2021 | $239.15 M(+41.0%) | $91.73 M(-570.2%) | $239.23 M(-22.8%) |
| Sept 2021 | - | -$19.51 M(-1167.3%) | $309.70 M(-6.1%) |
| June 2021 | - | $1.83 M(-98.9%) | $329.72 M(-1.9%) |
| Mar 2021 | - | $165.19 M(+1.8%) | $335.97 M(+97.2%) |
| Dec 2020 | $169.62 M(<-9900.0%) | $162.20 M(>+9900.0%) | $170.34 M(+2307.8%) |
| Sept 2020 | - | $506.00 K(-93.7%) | $7.07 M(+7.7%) |
| June 2020 | - | $8.08 M(-1910.8%) | $6.57 M(-535.6%) |
| Mar 2020 | - | -$446.00 K(-58.0%) | -$1.51 M(+42.0%) |
| Dec 2019 | -$155.00 K(-110.8%) | -$1.06 M | -$1.06 M |
| Dec 2018 | $1.44 M | - | - |
FAQ
- What is AbCellera Biologics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for AbCellera Biologics?
- What is AbCellera Biologics annual EBITDA year-on-year change?
- What is AbCellera Biologics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for AbCellera Biologics?
- What is AbCellera Biologics quarterly EBITDA year-on-year change?
- What is AbCellera Biologics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for AbCellera Biologics?
- What is AbCellera Biologics TTM EBITDA year-on-year change?
What is AbCellera Biologics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ABCL is -$192.16 M
What is the all time high annual EBITDA for AbCellera Biologics?
AbCellera Biologics all-time high annual earnings before interest, taxes, depreciation & amortization is $260.17 M
What is AbCellera Biologics annual EBITDA year-on-year change?
Over the past year, ABCL annual earnings before interest, taxes, depreciation & amortization has changed by -$452.32 M (-173.86%)
What is AbCellera Biologics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ABCL is -$51.88 M
What is the all time high quarterly EBITDA for AbCellera Biologics?
AbCellera Biologics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $235.12 M
What is AbCellera Biologics quarterly EBITDA year-on-year change?
Over the past year, ABCL quarterly earnings before interest, taxes, depreciation & amortization has changed by -$7.22 M (-16.18%)
What is AbCellera Biologics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ABCL is -$202.41 M
What is the all time high TTM EBITDA for AbCellera Biologics?
AbCellera Biologics all-time high TTM earnings before interest, taxes, depreciation & amortization is $372.64 M
What is AbCellera Biologics TTM EBITDA year-on-year change?
Over the past year, ABCL TTM earnings before interest, taxes, depreciation & amortization has changed by -$43.07 M (-27.03%)